Today, Sandoz announced that the EMA has accepted its Marketing Authorization Application for its biosimlar to Amgen’s Neulasta, used to prevent infection in patients with compromised immune systems due to chemotherapy. Sandoz’s application is supported by three pivotal clinical trials.
Related Content
- Big Molecule WatchApril 30, 2024
Biosimilar Approval Updates in Europe and China
- Big Molecule WatchApril 29, 2024
GSK Sues Pfizer, Pharmacia & Upjohn & BioNTech for Infringing mRNA Vaccine Patents
- Big Molecule WatchApril 29, 2024
Moderna Litigation Against BioNTech and Pfizer Stayed Pending IPR
- Big Molecule WatchApril 26, 2024
Alvotech Announces Positive Topline Results From Confirmatory Clinical Study for its Proposed Golimumab Biosimilar
- Big Molecule WatchApril 23, 2024
FDA Approval of Alvotech/Teva Ustekinumab Biosimilar
- Big Molecule WatchApril 22, 2024
DOJ Files False Claims Act Complaint Against Regeneron, Alleging Fraudulent Eylea Drug Pricing
- Big Molecule WatchApril 22, 2024
Federal Circuit Dismisses Appeals in Regeneron v. Mylan (Aflibercept) BPCIA Litigation
- Big Molecule WatchApril 19, 2024
Fresenius Kabi Announces Launch of TYENNE, a Tocilizumab Biosimilar Referencing ACTEMRA
- Awards and RankingsSeptember 25, 2023
Goodwin Named an LMG Life Sciences Life Cycle Firm for the Twelfth Consecutive Year
- Awards and RankingsOctober 4, 2022
LMG Recognizes Goodwin Lawyers and Practices for Excellence in Life Sciences
- Press ReleaseNovember 17, 2021
Goodwin Releases Update to its Comprehensive Guide to Biosimilars Litigation and Regulation in the U.S.
- Awards and RankingsOctober 26, 2021
Goodwin Named an LMG Life Sciences Life Cycle Firm for the Tenth Consecutive Year
- Press ReleaseJune 28, 2021
Goodwin Adds Life Sciences and Healthcare Litigation Partner William Jackson
- EventsDecember 5, 2020
China's Patent Linkage System: Can Strategies that Work in the U.S. System Be Applied to China?
- Awards and RankingsOctober 5, 2020
Goodwin Named An LMG Life Sciences Life Cycle Firm For The Ninth Consecutive Year
- Speaking EngagementsSeptember 23, 2020
ACI's 11th Summit on Biosimilars & Innovator Biologics